Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NALIRIFOX as Perioperative Treatment in Patients With High-risk Resectable Pancreatic Cancer : a Multicenter, Randomized, Open-label Trial

NCT06210360 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.

NCT NCT06210360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06210360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NALIRIFOX as Perioperative Treatment in Patients With High-risk Resectable Pancreatic Cancer : a Multicenter, Randomized, Open-label Trial
Lead sponsor
Changhai Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2024
Completion date
April 1, 2027
Enrollment
134 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer